PRABITAS study design: a pragmatic, randomized phase III trial of bi-weekly versus conventional trifluridine/tipiracil plus bevacizumab for metastatic colorectal cancer
-
Published:2024-09
Issue:
Volume:5
Page:100090
-
ISSN:2949-8198
-
Container-title:ESMO Gastrointestinal Oncology
-
language:en
-
Short-container-title:ESMO Gastrointestinal Oncology
Author:
Sakakida T.ORCID, Masuishi T.ORCID, Asayama M.ORCID, Mitani S.ORCID, Makiyama A., Shimura T.ORCID, Takeda H.ORCID, Suwa Y., Takano Y., Sawada K.ORCID, Yomoda T., Mushiake H.ORCID, Okumura Y.ORCID, Yokota M., Yamamoto M., Kito Y.ORCID, Ogawa K., Matsuoka H., Ando M.ORCID, Tajika M., Muro K., Kudo C., Mishima A., Murotani K.ORCID, Taniguchi H.ORCID
|
|